Advertisement

Reactions Weekly

, Volume 1744, Issue 1, pp 68–68 | Cite as

Blinatumomab/dasatinib/ponatinib

Various toxicities: 4 case reports
Case report
  • 25 Downloads

Reference

  1. Hanif A, et al. Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia. Leukemia and Lymphoma 59: 2011-2013, No. 8, Aug 2018. Available from: URL: http://doi.org/10.1080/10428194.2017.1411595 - USACrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations